CMS Lays Out Timeline For Biosimilar’s Effect On Stelara’s IRA Pricing

By Maaisha Osman / February 6, 2024 at 6:57 PM
Updated Story A CMS official laid out how the timing of the agency’s determination that Amgen is marketing its biosimilar Wezlana leads to differing scenarios for when Johnson & Johnson could get around Medicare’s upcoming negotiated price for Stelara, the brand version of the arthritis and psoriasis drug. Stelara is one of the 10 initial drugs for which CMS is negotiating a price under its new Inflation Reduction Act authority, and the agency says drugs facing “bona...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.